NM-2-AI

1. 2026-10-02issueIssued info_card
2. 2026-10-02srcThe metabolic fate of two new psychoactive substances - 2-aminoindane and N-methyl-2-aminoindane - studied in vitro and in vivo to support drug testing.
3. 2026-10-02srcAcute psychotropic, autonomic, and endocrine effects of 5,6-methylenedioxy-2-aminoindane (MDAI) compared with 3,4-methylenedioxymethamphetamine (MDMA) in human volunteers: A self-administration study.
4. 2026-10-02src2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and alpha2-adrenergic receptors
5. 2026-10-02srcPharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives.
6. 2026-10-02srcA snapshot on NPS in Italy: Distribution of drugs in seized materials analysed in an Italian forensic laboratory in the period 2013-2015
7. 2026-10-02srcDeath following consumption of MDAI and 5-EAPB
8. 2026-10-02srcEmerging toxicity of 5,6-methylenedioxy-2-aminoindane (MDAI): Pharmacokinetics, behaviour, thermoregulation and LD50 in rats.
9. 2026-10-02srcFirst toxicity profile of 2-aminoindane and N-Methyl-2-aminoindane using in silico multi-approach.
10. 2026-10-02srcCytotoxicity of new psychoactive substances and other drugs of abuse studied in human HepG2 cells using an adopted high content screening assay.
11. 2026-10-02srcMetabolism Study of N-Methyl 2-Aminoindane (NM2AI) and Determination of Metabolites in Biological Samples by LC-HRMS.
12. 2026-10-02srcLocomotor, discriminative stimulus, and place conditioning effects of MDAI in rodents.
13. 2026-10-02srcSynthetic Aminoindanes: A Summary of Existing Knowledge.
14. 2026-10-02srcBehavioral and Pharmacokinetics Studies of N-Methyl-2-Aminoindane (NM2AI) in Mice: An Aminoindane Briefly Used in the Illicit Drug Market.
15. 2026-10-02srcNovel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling
16. 2026-10-02srcSafety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects.
17. 2026-10-02srcSerotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a nonneurotoxic MDMA analogue.
18. 2026-10-02src(+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine as a discriminative stimulus in studies of MDMA-like behavioral activity.
19. 2026-10-02srcIn vitro actions of NN-dimethyl-2-aminoindane and related compounds.
20. 2026-10-02srcAminoindanes (UNODC Substance Group Details)
21. 2026-10-02srcN-Methyl-2-Aminoindane (NM-2-AI) Substance Details
22. 2026-10-02srcDEA Alert Regarding N-Methyl-2-Aminoindane (NM-2-AI)
23. 2026-10-02publicationPublication — publishagent-psx
24. 2026-10-02revisionr1.a1
25. 2026-10-02rulingRuling — psx:substance/nm-2-ai/proposal/article_section_proposals/31f2476e-5a3c-4a47-9794-d1c63df1f55ffounder
26. 2026-10-02rulingRuling — psx:substance/nm-2-ai/proposal/article_section_proposals/b0ff84c8-b65b-46d0-86e3-2372adf6356ffounder
27. 2026-09-04issueIssued emergency
28. 2026-09-04issueIssued info_card
29. 2026-09-04issueIssued notice
30. 2026-06-04proposal29 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
31. 2026-06-04publicationPublication — backfill
32. 2026-05-11revisionRevision 1
33. 2026-05-11absenceSearched ClinicalTrials.gov for "aminoindane NM-2-AI 2-aminoindane" — no results
34. 2026-05-11genGeneration — pipeline-v5 · with 3 morepipeline-v5
35. 2026-05-11rungeneration run

The same entries, as forms: six forms.